These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
50. FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia. Cools J Verh K Acad Geneeskd Belg; 2005; 67(3):169-76. PubMed ID: 16089297 [TBL] [Abstract][Full Text] [Related]
51. Endomyocardial Fibrosis With End-Stage Heart Failure as a Consequence of a Myeloproliferative Neoplasm With Hypereosinophilia. Strong C; Abecasis J; Afonso C; Trabulo M; Gouveia R Can J Cardiol; 2018 Sep; 34(9):1233.e13-1233.e15. PubMed ID: 30170680 [TBL] [Abstract][Full Text] [Related]
52. Hypereosinophilic Syndrome as a Rare Cause of Reversible Biventricular Heart Failure. Bonou M; Kapelios CJ; Benetos G; Moyssakis I; Giannakopoulou N; Diamantopoulos P; Korkolopoulou P; Variami E; Barbetseas J Can J Cardiol; 2017 May; 33(5):688.e5-688.e7. PubMed ID: 28347583 [TBL] [Abstract][Full Text] [Related]
53. [A man with oral ulcers caused by hypereosinophilic syndrome and a good response to the tyrosine-kinase inhibitor imatinib]. Verstappen MC; Mattijssen V; van der Reijden BA; van der Heijden AJ; Wahab PJ; de Vries RA Ned Tijdschr Geneeskd; 2006 May; 150(21):1188-92. PubMed ID: 16768284 [TBL] [Abstract][Full Text] [Related]
54. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. Pardanani A; Tefferi A Leuk Res; 2004 May; 28 Suppl 1():S47-52. PubMed ID: 15036941 [TBL] [Abstract][Full Text] [Related]
55. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Lierman E; Michaux L; Beullens E; Pierre P; Marynen P; Cools J; Vandenberghe P Leukemia; 2009 May; 23(5):845-51. PubMed ID: 19212337 [TBL] [Abstract][Full Text] [Related]
56. [Durable efficacity and remission after treatment with imatinib mesylate for FIP1L1-PDGFRA transcript negative associated eosinophilic cardiomyopathy]. Sekkach Y; Mekouar F; Jira M; Elqatni M; Elomri N; Fatihi J; Badaoui M; Hammi S; Smaali J; El Khattabi A; Amezyane T; Abouzahir A; Ghafir D Ann Pharm Fr; 2011 Sep; 69(5):277-81. PubMed ID: 21924129 [TBL] [Abstract][Full Text] [Related]
57. [FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutant of PDGFRA gene: a case report and literature review]. Qu SQ; Wang Y; Sun XJ Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):159-61. PubMed ID: 23611226 [No Abstract] [Full Text] [Related]
58. Two cases with hypereosinophilic syndrome shown with real-time PCR and responding well to imatinib treatment. Selvi N; Kaymaz BT; Sahin HH; Pehlivan M; Aktan C; Dalmızrak A; Inalpolat E; Kosova B; Yılmaz M; Okan V; Saydam G Mol Biol Rep; 2013 Feb; 40(2):1591-7. PubMed ID: 23076533 [TBL] [Abstract][Full Text] [Related]
59. Chronic eosinophilic leukaemia revealed by lymphomatoid papulosis: the role of the FIP1-like 1-platelet-derived growth factor receptor alpha fusion gene. Thuny C; Gaudy-Marqueste C; Nicol I; Gabert J; Costello R; Grob JJ; Richard MA J Eur Acad Dermatol Venereol; 2010 Feb; 24(2):234-5. PubMed ID: 19686260 [No Abstract] [Full Text] [Related]
60. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells. Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]